Skip to content

Optimization Study on Community Screening Strategies for Prostate Cancer in Elderly Men with Serum PSA Levels of 2-4 ng/ml

Optimization Study on Community Screening Strategies for Prostate Cancer in Elderly Men with Serum PSA Levels of 2-4 ng/ml

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500115256
Enrollment
Unknown
Registered
2025-12-24
Start date
2025-12-25
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Gold Standard:Pathological Results of Prostate Biopsy
Index test:PSA,MRI,Urine Exosomes

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Male individuals aged 60 or above; 2. The serum total PSA (tPSA) level is between 2.0 and 4.0 ng/ml, and the test result is the latest physical examination result. 3. Recently, there have been no oral medications such as finasteride or epiplate that affect PSA levels. 4. No history of prostatic puncture; 5. Agree to undergo urine sample collection, prostate MRI examination and biopsy if necessary, and sign the informed consent form; 6. Have the status of a permanent resident of a community in Beijing and be able to be followed up stably;

Exclusion criteria

Exclusion criteria: 1.Individuals with a previous clear diagnosis of prostate cancer; 2.History of recent prostate-related procedures (within the past 3 months) that may affect PSA levels, such as catheterization, cystoscopy, or digital rectal examination; 3.Active urinary tract infection or acute phase of prostatitis; 4.Severe underlying medical conditions, malignancy, or significant cognitive impairment that may interfere with compliance to the study procedures; 5.Contraindications to MRI examination, such as implanted cardiac pacemakers, metallic foreign bodies, or claustrophobia;

Design outcomes

Primary

MeasureTime frame
Detection rate of prostate cancer;

Secondary

MeasureTime frame
Accuracy analysis of the combined MRI and PSMA-EVs model;Biopsy positivity rate;MRI positivity rate;Diagnostic performance of PSMA-EVs testing;Incidence of newly diagnosed prostate cancer during follow-up;Proportion of clinically significant prostate cancer;

Countries

China

Contacts

Public ContactLiu Ming

Beijing Hospital

liuming19731029@163.com+86 10 8513 6271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026